|View printer-friendly version|
|Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference|
A live and archived audio webcast of the presentation will be available under the News & Investors section of Chiasma’s website at www.chiasma.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The Company recently initiated CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated following SPA agreement with the